Compare Lithium Americas Corp (LAC) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lithium Americas Corp vs Zimmer Biomet Holdings Inc — how do they compare? Lithium Americas Corp trades at $2.36 (market cap $850.38M), while Zimmer Biomet Holdings Inc trades at $89.91 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 19.9× Lithium Americas Corp's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while Lithium Americas Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lithium Americas Corp for 27 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| LAC | ZBH | |
|---|---|---|
Market Cap | $850.38M | $16.95B |
Volume | 8,804,637 | 2,505,240 |
Sector | Basic Materials | Health |
52-Week High | $10.05 | $103.98 |
52-Week Low | $2.36 | $79.58 |
Typical Hold Time | 27 Days | 89 Days |
Enterprise Value | $1.19B | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lithium Americas (LAC) trades at $2.35, down 2.49% on the day, with a bearish technical outlook despite recent earnings beats. The company shows negative profitability metrics (ROE -9.56%, ROA -3.99%) and zero revenue in 2025, though construction progress at Thacker Pass provides potential upside. Analyst consensus is mixed with 7 buy and 8 hold ratings, pointing to a $4.00 price target representing 70% upside from current levels.
LAC presents a high-risk, high-reward opportunity as it transitions from development to execution phase. The primary investment thesis hinges on successful Thacker Pass development and lithium price recovery, while key risks include project execution challenges, negative cash flow from operations, and volatile lithium markets. Current valuation at 0.6x book value suggests potential undervaluation if operational milestones are met.
Zimmer Biomet (ZBH) trades at $89.14, up 0.73% today, with a bearish technical signal but strong recent earnings beats. The stock shows robust fundamentals with a 69.87% gross margin and 2025 revenue of $8.23B, though net income margin has declined from 2023 peaks. Analyst consensus is a Buy with a $103.11 target, indicating potential upside, supported by a steady dividend and institutional accumulation.
The outlook is mixed: valuation metrics like a P/E of 21.57 appear reasonable, and earnings momentum is positive, but technical weakness and rising debt-to-asset ratios pose risks. Investment appeal hinges on execution of commercial transformations and procedure volume recovery, balancing growth prospects against competitive and operational headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lithium Americas Corp
Lithium Americas is a resource company focused on developing the Thacker Pass project in Nevada, the largest known lithium resource in the US. It aims to become a major supplier for the electric vehicle battery market.
Read more on LAC →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
